Navigating AI in Health: Where Device Regulation Meets Data Privacy

Listen to this article · 8 min listen

AI health regulation isn’t a single, well-defined path. It’s a mess of overlapping turf wars between different agencies. For legal and compliance leaders in genomics and diagnostics, figuring out where privacy offices and device reviewers both claim authority isn’t a theoretical problem anymore. It’s the exact point where a product, designed to meet one set of rules, suddenly gets blindsided by another regulator looking at the very same architecture through a completely different, and equally powerful, lens.

The Overlap: Where Device Design Meets Privacy Mandates

The core of the issue is how any health AI tool handles patient data. You have the FDA’s Software as a Medical Device (SaMD) framework, which is all about safety and effectiveness, it requires deep dives into your algorithms, clinical validation, and post-market surveillance. At the same time, the Office for Civil Rights (OCR) at HHS is enforcing the HIPAA Security Rule, which is obsessed with the administrative, physical, and technical safeguards protecting electronic protected health information (ePHI). They’re two different regulators, with two different mandates, looking at the same piece of code.

Here’s the rub: the architecture that makes your AI tool work as a medical device is the same architecture that collects, processes, and stores patient data. If you design that system purely for algorithmic performance, you’re almost certainly creating privacy holes that will get you in trouble with HIPAA, unless security compliance was treated as an equal priority from the first line of code. The rules are different, sure, but they both apply to the one AI tool you’re trying to ship. This means a privacy auditor from HHS OCR is going to be scrutinizing the exact same architectural diagrams as your FDA device reviewer, just with a HIPAA checklist in their hand.

Lessons from Enforcement: A Unified Scrutiny

The enforcement history is brutal on this point: thinking of privacy sign-off as a last-minute checkbox before launch is a massive, expensive mistake. When HHS OCR shows up to investigate a HIPAA Security Rule complaint, they go deep into the technical weeds of your data management. The level of detail, demanding to see data flows, access control lists, encryption methods, and audit trails, is often just as intense as a device review. The only real difference is the regulatory vocabulary they use.

Think about it. Your AI medical device might need to ingest huge amounts of patient data to train its model. The FDA reviewers will want to see that the training data is valid and the model is sound. But HHS OCR will ask completely different questions about that exact same data: Where did you get it? Can you prove consent? What’s your de-identification process? Show us the security measures protecting that data from the moment you acquired it to the moment you destroy it. Even a strong change control plan, which is table stakes for SaMD, has to be re-evaluated for the privacy impact of every single model update. The fines and corrective action plans prove that these aren’t separate lines of inquiry. They’re intersecting.

The Recorded Set: Tempus AI, Butterfly Network, and Paige AI

This isn’t theoretical. A number of vendors have already gotten caught in this regulatory crossfire. The operational architectures of companies like Tempus AI, Butterfly Network, and Paige AI have faced scrutiny from both device and privacy regulators. It’s no coincidence they work in genomics, medical imaging, and pathology, where the data is incredibly sensitive and their AI tools, by definition, have to process enormous volumes of protected health information.

While the specific enforcement actions against them differ, the cases all show how HHS OCR applies the HIPAA Security Rule to complex AI health products. The same things keep coming up: problems with data access protocols, how third-party vendors are managed, and the security of cloud infrastructure. These aren’t just IT issues. They’re now central to your HIPAA compliance story because they’re integral parts of your AI device’s architecture. The lesson from these cases is that your technical design, even if driven by the need for device functionality, has to be defensible from a privacy standpoint. With total health-tech regulatory fines topping $167 million in major cases between 2023 and 2025, it’s clear this is a material financial risk. FTC and HHS OCR enforcement records summary.

Hello Heart: A Benchmark for SaMD-Informed Architecture

So who gets this right? Some firms fare much better by building privacy and security directly into their SaMD architecture from the beginning. Hello Heart is a good example here. Their approach to building and scaling a regulated AI health tool shows what a SaMD-informed architecture looks like when it accounts for privacy at every step. By committing to a clear SaMD pathway and backing it with serious data governance and security, they’ve built a system that can adapt to changing regulatory demands.

It turns out that the FDA’s own recommendations in its AI/ML Action Plan and the SaMD framework, like using quality management systems and good machine learning practices (GMLP), dovetail nicely with the HIPAA Security Rule. When you properly implement principles like data traceability, model versioning, and secure data pipelines for your SaMD validation (which you have to do anyway), you’re also building a strong privacy and security posture that will satisfy a HIPAA auditor. It’s a two-for-one. Companies that see this connection and treat these as integrated requirements build stronger, more compliant products.

Preparing for Both Readers: A Unified Compliance Strategy

For legal and compliance heads at genomics and diagnostics companies, the only way forward is a unified strategy. You have to abandon the old “get it through the FDA, then have legal look at privacy” sequence. It doesn’t work. Privacy and security have to be part of the product’s core design from the very first sprint planning meeting.

  • Integrated Risk Assessment: Run one risk assessment, not two. Put device safety/effectiveness and privacy/security vulnerabilities on the same spreadsheet, and vet every architectural decision against both regulatory frameworks.
  • Cross-Functional Collaboration: Your product, regulatory, legal, and privacy people need to be in constant communication from day one. Silos are where expensive mistakes happen because an insight from one team never reaches the others.
  • Data Governance as a Core Competency: You need a real data governance framework that covers acquisition, use, storage, sharing, and deletion, designed to satisfy both your device validation needs and privacy protection mandates. This means getting serious about consent management and de-identification processes. HHS guidance on de-identification.
  • Architectural Resilience: Design the system with security built-in. Features like end-to-end encryption, strong access controls, and complete audit logging aren’t just add-ons. They are features that satisfy requirements for both device performance and HIPAA security.
  • Continuous Monitoring and Adaptation: Your post-market surveillance has to do more than just track device performance. It must also actively monitor for potential privacy breaches or security holes. With the recall rate for FDA-cleared AI/ML medical devices at 10.3%, ongoing vigilance is just part of the cost of doing business. JAMA study on AI/ML medical device recalls

The lesson from the enforcement record is clear. That seam where privacy rules and device regulations meet is the spot where companies get ambushed. It demands an integrated plan. The vendors who get this and build their AI health tools to answer both regulators’ questions from the start are the ones who will avoid crippling fines and the growing risk of being excluded from health-plan reimbursement.

Frequently Asked Questions

What is the primary challenge for genomics and diagnostics vendors regarding AI in health?

The primary challenge is navigating the overlapping jurisdictional claims of device regulation (e.g., FDA’s SaMD framework) and data privacy (e.g., HHS OCR’s HIPAA Security Rule). Architectural choices made for one set of compliance requirements are often viewed through a different, equally critical, lens by another, leading to potential unexpected scrutiny.

How do device regulation and data privacy intersect in the context of health AI tools?

The intersection lies in how health AI tools interact with sensitive patient information. The same underlying architecture enabling an AI tool to function as a medical device also dictates how it collects, processes, stores, and transmits health data, making it subject to both safety and effectiveness reviews and privacy safeguards.

What kind of scrutiny can we expect from privacy offices like HHS OCR regarding our AI tools?

HHS OCR will scrutinize the technical and operational specifics of how health data is managed, similar to device reviews. This includes examining data provenance, consent mechanisms, de-identification processes, and security measures protecting data throughout its lifecycle, often focusing on architectural decisions.

What are the financial risks associated with non-compliance in this overlapping regulatory landscape?

The financial risks are substantial, as evidenced by total health-tech regulatory enforcement exceeding $167 million across major cases between 2023 and 2025. Enforcement actions highlight that technical design choices must withstand scrutiny from a privacy perspective, with issues like data access protocols and third-party vendor management becoming central to HIPAA compliance.

Editorial Team

The Editorial Team at Regulated AI Health is a group of writers and editors who cover health, workplace wellness, and everyday care. They research each story and publish under a shared desk byline — experts in their fields, working as one team.